i-SEP - the alternative to allogeneic blood transfusions

i-SEP is a Medtech based in Nantes (Upper Brittany, France) focusing on IntraOperative Cell Salvage (IOCS) or Autotransfusion and Patient Blood Management (PBM).

i-SEP has developed and markets a patented innovative technology for the separation of blood components.

Technology

i-SEP markets a new generation of IntraOperative Cell Salvage technology (IOCS) for use in hemorrhagic or high-risk hemorrhagic surgery, capable of recovering not only red blood cells but also the patient’s platelets.

Events & news

Keep up to date with what’s going at i-Sep

i-SEP 6 days ago

💭 Looking back at hashtag#NATA25 at the Science Congress Center in Munich! To celebrate its 25th anniversary, NATA brought together experts and practitioners from around the world to discuss the major challenges in transfusion medicine. This year, the debates focused in part on Patient Blood Management (PBM), a true public health challenge. A must-attend event that drives innovation and advances clinical practices. And we are proud that i-SEP was part of it. A few highlights: 👉 Dr. Bertrand Rozec (CHU de Nantes) spoke during the session "Cell Salvage: The Past, Present and Game-Changing Future", highlighting emerging technologies in the operating room, including our same™ solution. 👉 On friday morning, our joint symposium with HemoSonics shed light on blood management in cardiac surgery and obstetric: from coagulation monitoring with Quantra® and qLabs® FIB to comprehensive autotransfusion (platelets + red blood cells) thanks to same™. We had the pleasure of hearing inspiring talks from Aryeh Shander, Anne-Sophie Ducloy-Bouthors and Dr. med. Gösta Lotz, DESA, MA. 👉 Finally, our booth became a real hub for exchange, where we showcased our same™ technology. 💡 Why same™? Our solution addresses a major public health issue. By enabling hemorrhagic patients to recover both their red blood cells and their own platelets, i-SEP provides an impactful solution that offers significant patient benefits and cost savings for healthcare systems. In the context of strained blood management, this is an innovative solution that represents a major step forward in transfusion strategy. 📆 Next stop: Lisbon Join us at the European Society of Anaesthesiology and Intensive Care Congress, from May 25-27, 2025!

i-SEP 1 week ago

📍 Live from #NATA25 in Munich! This morning, we had the pleasure of co-hosting a symposium with our partner HemoSonics, focusing on cardiac surgery and obstetrics, and exploring innovative approaches in coagulation monitoring and autotransfusion. 🕘 9:00 – 10:00 AM 📍 Audimax – Plenary Room Topic: “Patient Blood Management in cardiac surgery and obstetrics: from coagulation monitoring with Quantra® & qLabs® FIB to comprehensive autotransfusion (platelets + red blood cells) with same™” A big thank you to our speakers for their insightful presentations: ➡️ Aryeh Shander : "Introduction and Current State of PBM" ➡️ Anne-Sophie Ducloy-Bouthors : "Coagulation monitoring in obstetrics with Quantra® and qLabs® FIB" ➡️ Dr. med. Gösta Lotz, DESA, MA : "Initial feedback on same™ in Frankfurt: comprehensive autotransfusion (Platelets + RBC)" Our same™ technology is redefining transfusion strategies by enabling patients to recover their own red blood cells and platelets, significantly reducing the need for donor blood. 👋 Visit Guillaume Laurent and Georges Tabary at booth 1-02 to discover our solution and connect with us.

i-SEP 1 month ago

📌 We were present at the J.E.P.U. Anesthesia & Intensive Care Congress with Stago BioCare! Each year, this congress brings together over 3,000 anesthesiologists and nurse anesthetists for two days of discussions on the latest advancements in the field, with around one hundred speakers and fifty exhibitors. A big thank you to everyone who stopped by to learn more about our same™ technology. 🩸 Our solution addresses a major public health issue. By enabling patients to recover their own red blood cells and platelets during hemorrhagic surgeries, i-SEP delivers significant benefits to patients while also generating cost savings for our healthcare system. In a context of increasing pressure on blood resources, this is an innovative solution that represents a major step forward in transfusion strategy. 📆 Save the date: Join us on April 24, 25, and 26 in Munich for the NATA congress.

i-SEP 3 months ago

Celebrating Our First Participation at The Society of Thoracic Surgeons hashtag#STS2025 in Los Angeles As the Society of Thoracic Surgeons (STS) Annual Meeting in Los Angeles comes to a close today, we are proud to have showcased our system for the very first time in the United States. This marks a significant milestone in our journey to contribute to innovation in the cardiothoracic field. In the face of increasing pressure on blood reserves, i-SEP presents a major innovation for patients and healthcare professionals : sam™ system*, which is revolutionizing platelet and red blood cell (RBC) autotransfusion in cardiac surgery. 🙏We want to thank everyone who visited our booth, engaged in discussions, and shared valuable insights. Your support and enthusiasm mean the world to us. Our thoughts remain with those affected by the recent wildfires in the region. The resilience of this community is truly inspiring. This is just the beginning of our adventure, and we look forward to what’s ahead as we continue to grow and collaborate with this amazing community.

Expertise

Autotransfusion, the alternative to
allogenic transfusions